Telomir Pharmaceuticals Unveils Positive Preclinical Results for Telomir-1 in Wilson's Disease

Telomir Pharmaceuticals, Inc. has announced promising preclinical results for Telomir-1, its lead drug candidate, in treating Wilson's disease. This rare genetic disorder causes harmful copper accumulation, leading to severe organ dysfunction. Telomir-1 significantly reversed neurological, liver, and kidney symptoms in an animal model, reducing copper accumulation and improving survival rates.

The study revealed that Telomir-1 reduced tremors and anxiety-like behaviors and improved motor functions. Notably, it normalized critical liver biomarkers, indicating protection against liver damage. The drug's demonstration of broad regenerative potential aligns with earlier findings in Werner syndrome and Age-Related Macular Degeneration.

Telomir aims to enter human clinical trials for rare diseases by 2026. This advancement marks a significant step in their mission to develop therapies tackling degenerative disorders through biological aging reversal.